Ardelyx Presents Real-World Data Showing Significant Reduction In GI-Related Healthcare Resource Utilization After IBSRELA Initiation, At ACG 2026 Annual Meeting
Ardelyx, Inc. (NASDAQ:ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced results from
Ardelyx showed that their medicine helps people with stomach problems. This suggests the medicine is working well in real life.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.